J Drug Target (2022) 30:96172
Purpose-built for physicians Combination GLP-1, hormone therapy may reduce risk for endometrial cancer Key takeaways: Adding GLP-1s to progestin therapy appeared to reduce the risk for endometrial cancer among women with benign uterine or endometrial hyperplasia
Regular follow-up appointments let your provider monitor your progress and adjust treatment as needed
Several research studies have used bone mineral density and lean body mass to measure how GLP-1 medications affect the body
Inner ear problems may be overlooked, but they are a very common cause of dizziness
Direct GLP-1 Receptor-Mediated Immune Modulation Semaglutide activates GLP-1 receptors on immune cells, which: Suppresses the NF-kB signaling pathway, a master regulator of inflammatory gene expression (8) Reduces the production of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta) Shifts macrophage polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype (10) Modulates T-cell responses, potentially reducing autoimmune-driven inflammation Weight Loss and Visceral Fat Reduction Visceral fat is not merely a storage depot it is an active endocrine organ that produces a constant stream of inflammatory cytokines
